2208-08-4

Basic information

• Product Name: ETHYL BUTYRIMIDATE HYDROCHLORIDE
• Synonyms: ethyl butanimidate hydrochloride;Ethyl butyrimidate hydrochloride >=97.0% (AT);butyrimidicacid,ethylester,hydrochloride;ethyl butanecarboximidate hydrochloride
• CAS NO: 2208-08-4
• Molecular Formula: C₆H₁₃NO*ClH
• Molecular Weight: 151.63446
• Mol File: 2208-08-4.mol

Chemical Properties

• Melting Point: 74-79 °C
• Boiling Point: 114.4 °C at 760 mmHg
• Flash Point: 23 °C
• Appearance: /
• Vapor Pressure: 23.7mmHg at 25°C
• Storage Temp.: 2-8°C
• BRN: 3679641
• CAS DataBase Reference: ETHYL BUTYRIMIDATE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL BUTYRIMIDATE HYDROCHLORIDE(2208-08-4)
• EPA Substance Registry System: ETHYL BUTYRIMIDATE HYDROCHLORIDE(2208-08-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• RTECS: ET7250000
• F: 3-10-21
• Hazardous Substances Data: 2208-08-4(Hazardous Substances Data)

Usage

Uses

Used in Biochemistry and Molecular Biology Research:
ETHYL BUTYRIMIDATE HYDROCHLORIDE is used as a crosslinking agent for covalently linking carboxyl groups to primary amines in proteins, peptides, and nucleic acids. This helps researchers study and manipulate biological molecules in various applications.
Used in the Production of Antibody Drug Conjugates:
ETHYL BUTYRIMIDATE HYDROCHLORIDE is used as a conjugation agent for the production of antibody drug conjugates. It aids in the attachment of therapeutic agents to antibodies, enhancing the targeting and delivery of drugs to specific cells or tissues.
Used in Protein Labeling:
ETHYL BUTYRIMIDATE HYDROCHLORIDE is used as a labeling agent for proteins. It enables the attachment of various labels, such as fluorescent tags or biotin, to proteins for detection, tracking, or purification purposes.
Used in the Immobilization of Enzymes:
ETHYL BUTYRIMIDATE HYDROCHLORIDE is used as an immobilization agent for enzymes. It helps in attaching enzymes to solid supports, which can improve their stability, reusability, and catalytic efficiency in various industrial and research applications.

InChI:InChI=1/C6H13NO.ClH/c1-3-5-6(7)8-4-2;/h7H,3-5H2,1-2H3;1H

Upstream product

• 109-74-0 propyl cyanide 
• 64-17-5 ethanol 

Downstream Products

• 24964-76-9 triethyl orthobutyrate 
• 541-35-5 butanamide 
• 75-00-3 chloroethane 
• 154460-63-6 (4R,5S)-4-Methyl-5-phenyl-2-propyl-4,5-dihydro-oxazole 
• 115591-36-1 C₁₀H₁₄N₄O₂ 
• 148236-54-8 2-propyl-1,3-diazaspiro[4.4]non-1-en-4-one 
• 99840-45-6 4-methyl-2-propyl-1H-benzimidazole 
• 1170669-68-7 N-4-fluoro-3-iodobenzoylbutanimidic ethyl ester 
• 1170669-88-1 C₅₃H₇₂FNO₄ 
• 1206697-02-0 (5-propyl-4H-1,2,4-triazol-3-ylmethyl)carbamic acid benzyl ester 
• 790631-35-5 N-(2H-Pyrazol-3-yl)-butyramidine 
• 437717-21-0 N'-(1-iminobutyl)-2-ethoxybenzohydrazide hydrochloride 
• 554-68-7 triethylamine hydrochloride 
• 146650-89-7 ethyl 5-methyl-2-propyl-3H-imidazole-4-carboxylate 

Relevant articles and documents

Preparation method of telmisartan intermediate

The invention relates to a preparation method of a telmisartan intermediate, namely 2-n-propyl-4-methyl-6-Benzimidazolecarboxylic acid. The preparation method of the 2-n-propyl-4-methyl-6-Benzimidazolecarboxylic acid comprises the following steps: firstly, ethanol hydrochloride acts with butyronitrile and anhydrous hydrogen chloride within the range of 0-35 DEG C; the mixture obtained in the firststep reacts with 3-methyl-4-aminobenzoic acid and ice vinegar within the range of pH 5.0-11.0 at the controlled temperature of 10-40 DEG C, and an intermediate shown in the formula II is obtained; and then the intermediate shown in the formula II reacts with a sodium hypochlorite solution, and the 2-n-propyl-4-methyl-6-Benzimidazolecarboxylic acid is obtained. The intermediate preparation processis suitable for industrial production, and meanwhile the product quality is improved.

'Green' synthesis of 2-substituted 6-hydroxy-[3H]-pyrimidin-4-ones and 4,6-dichloropyrimidines: Improved strategies and mechanistic study

An improved route to 2-substituted 6-hydroxy-[3H]-pyrimidin-4-ones 4 and to 2-substituted 4,6-dichloropyrimidines 5 is reported. Without using highly toxic reactants, compounds 4 can be prepared conveniently in a one pot synthesis on a one mol scale with average yields up to 80%. 4,6-Dichloropyrimidines 5, which are usually prepared in small quantities, are synthesized with average yields of 80%, using up to 80g of starting material. The mechanism of the chlorination of 4 is investigated computationally for the first time. The results suggest that the chlorination with phosphoryl chloride occurs in an alternating phosphorylation-chlorination manner (pathway 1) which is preferred over a sequence which starts with two phosphorylations. The investigated 4,6-dichloropyrimidines described herein form strong complexes with dichlorophosphoric acid but weak complexes with hydrochloric acid (generated during workup). These latter complexes explain the necessity of using aqueous sodium carbonate during the working up. In order to prevent possible formation of pyrimidinium salts between intermediates or the final dichloropyrimidines and unreacted hydroxypyrimidone, the latter could be deactivated with a strong acid such as dichlorophosphoric acid, thus allowing chlorination but prohibiting salt formation. Because of its general applicability to all nitrogen heterocycle chlorinations with phosphoryl chloride, the proposed route to dichloropyrimidines without solvent or side products, using less toxic reactants, is of general synthetic interest.

SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES

The present invention relates to polysubstituted imidazolone derivatives, to the pharmaceutical compositions comprising them and to the therapeutic uses thereof in the human and animal health fields. The present invention also relates to a process for preparing these derivatives.

Pyrazolotriazines

Compounds of a certain formula I, in which R1, R2, A, R4, B, R5 and R6 have the meanings indicated in the description, are effective compounds with anti-proliferative and/or apoptosis inducing activity.

NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE AT1 AND ETA RECEPTORS

The present invention relates to new compounds of the formula [Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, R3, and R31 are as specified herein. The invention also relates to a method for preparation thereof, as well as combinations of the new compounds with previously known agents. The invention also relates to the use of the above-mentioned compounds and combinations for the preparation of a medicament for treating hypertension of different kinds, alleviating organ damage of different kinds, treating or preventing diabetic nephropathy, treating endothelin and angiotensin mediated disorders, and treating prostate cancer.

Convenient synthesis and physicochemical profile of new derivatives of pyrimidine

A synthesis of linear oligoheterocycles based on the substituted pyrimidines are described. The desired compounds have been accomplished by the variation of the original Pinner synthesis in which the aliphatic nitrile reacted with hydrogen chloride to give imino ester. These compound reacted with ammonia gas to give amidine. Chalcones in reaction with amidines give bis(phenyl)pyrimidines. The bis(phenyl)pyrimidines reacted with 3,4-ethylenedioxy-2-trimethyltinthiophene or 2-trimethyltinthiophene in the presence of Pd(PPh3)2Cl2 or Pd(PPh3)4 as catalyst to give designed compounds. In this work are presented also some electrochemical measurements using Langmuir-Blodgett technique in mono-and binary systems.

Method for the production of 2-(2-ethoxyphenyl)-substituted imidazotriazinones

The invention relates to a method for the production of 2-phenyl-substituted imidazotriazinones of general formula (I), comprising the reaction of compounds of formula (II) with compounds of formula (III) and subsequent reaction with iodine or bromine, th

The role of the side chain in determining relative δ- and κ-affinity in C5′-substituted analogues of naltrindole

The role of the side chain in 5′-substituted analogues of naltrindole has been further explored with the synthesis of series of amides, amidines, and ureas. Amidines (8, 13) had greatest selectivity for the K receptor, as predicted from consideration of the message-address concept. It was also found that an appropriately located carbonyl group, in ureas (10) and amides (7), led to retention of affinity and antagonist potency at the δ receptor.

MITOTIC KINESIN INHIBITORS

The present invention relates to dihydropyrimidone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositi

Benzimidazole derivatives

Disclosed herein are compounds of formula I or II: wherein R is alkyl phenyl or substituted phenyl; R2is hydrogen, halogen, alkoxy or alkyl; R1is hydrogen, alkyl, aryl, arylalkyl, or substituted benzyl; or a pharmaceutically acceptab